Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 7, 2025 • 12:00 PM ET

Date/Time Source News Release
06/03/2025 07:50 AM EDT GlobeNewswire Quantum BioPharma Clarifies It Has Not Changed Its Name
06/02/2025 01:47 PM EDT GlobeNewswire iNGEN? CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
05/30/2025 07:00 AM EDT GlobeNewswire Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
05/29/2025 07:30 AM EDT GlobeNewswire Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
05/28/2025 08:00 AM EDT GlobeNewswire Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
05/21/2025 08:00 AM EDT GlobeNewswire Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
05/20/2025 07:30 AM EDT GlobeNewswire Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
05/19/2025 07:30 AM EDT GlobeNewswire Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
05/16/2025 07:30 AM EDT GlobeNewswire Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
05/12/2025 08:00 AM EDT GlobeNewswire Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
Page

Additional News

As of June 7, 2025 • 12:00 PM ET

Date/Time Source News Release
06/03/2025 10:30 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd 
05/30/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
05/29/2025 10:55 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
05/28/2025 09:45 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
05/21/2025 09:25 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps BitGo to Safeguard Crypto Assets
05/21/2025 08:52 AM EDT SeekingAlpha Quantum BioPharma selects BitGo to securely store its cryptocurrency assets;
05/20/2025 09:15 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial
05/19/2025 07:45 AM EDT SeekingAlpha Quantum Biopharma buys additional $1 million of Bitcoin, other cryptocurrencies
05/12/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for MS Drug Candidate
05/09/2025 01:58 AM EDT Stock Traders Daily How To Trade (QNTM)
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.